Physician profile
Jamie Steinert
NPI 1528119831
$2,345.36
in general payments reported to CMS, 2019-2025
10 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $534 · 2022: $517 · 2023: $438 · 2024: $388 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,294.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $690.51 | 2022-2025 | Caplyta |
| Alkermes, INC. | $593.83 | 2021-2025 | Lybalvi |
| Teva Pharmaceuticals USA, INC. | $345.33 | 2021-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $310.77 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $164.05 | 2021-2022 | |
| Bausch Health US, LLC | $121.13 | 2021-2024 | Aplenzin |
| Abbvie INC. | $34.95 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $33.34 | 2021 | |
| Validus Pharmaceuticals LLC | $31.65 | 2024 | Equetro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.80 | 2025 | Rejoyn |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Steinert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.